Mary T. Szela

Mary T. Szela has filed trades across 5 companies (mainly through SEC (Form 4)), most often in TriSalus Life Sciences, Inc., Coherus Oncology, Inc. and Absci Corp. We count 20 filings; the first trade dates from 9 May 2017 and the latest from 5 October 2026.

The open-market side counts 5 purchases for €318k alongside 2 sales for €873k. Sales outweigh purchases by €555k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 8 share grants and 4 option exercises. In 2026 alone, the filings show 2 purchases and 1 sale.

The median purchase comes to €35k. Clusters matter here: 1 out of 5 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 20% of cases; the median change was -12.2%. These figures describe past trades and do not predict future prices.

The record was last updated on 7 October 2026 with a share grant (€10k) in TriSalus Life Sciences, Inc. The last purchase on record was published on 6 July 2026, which is 107 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.